Get started
Author

Florence Lerebours

Observed name: F. Lerebours
ORCID: 0009-0006-1895-4269
Observed ORCID: 0009-0006-1895-4269
OpenAlex ID: A5029223255
Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO)
2019 · Agnes Dumas, Ines Vaz Luis, et al. · Journal of Clinical Oncology · 132
PDF
Association with pregnancy increases the risk of local recurrence but does not impact overall survival in breast cancer: A case–control study of 87 cases
2015 · A.S. Genin, Y. De Rycke, et al. · The Breast · 32
Cognition and Return to Work Status 2 Years After Breast Cancer Diagnosis
2024 · Marie Lange, Justine Lequesne, et al. · JAMA Network Open · 27
Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial
2025 · Hervé Bonnefoi, Florence Lerebours, et al. · The Lancet Oncology · 25
HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer
2025 · Veronique Dieras, Giuseppe Curigliano, et al. · Journal of Clinical Oncology · 20
Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
2023 · Maxim De Schepper, Ha-Linh Nguyen, et al. · Cancer Research Communications · 8
PDF
Treatment toxicities and pathological response through the evolution of neoadjuvant regimens in early triple-negative breast cancer
2025 · E. Arnaud, P. Vaflard, et al. · ESMO Real World Data and Digital Oncology · 4
PDF
Working conditions associated with return to work 2 years after breast cancer: insights from a cohort study
2025 · Garazi Ruiz de Azua, Idlir Licaj, et al. · British Journal of Cancer · 3
Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study
2025 · Mylène Duivon, François Christy, et al. · Breast Cancer Research · 3
PDF
Whole-exome profiles of inflammatory breast cancer and pathological response to neoadjuvant chemotherapy
2024 · François Bertucci, Arnaud Guille, et al. · Journal of Translational Medicine · 2
PDF
Abstract PO2-04-10: Effect of Alpelisib Dose Modification for AE Management on Progression-Free Survival and Treatment Duration in SOLAR-1 and BYLieve Clinical Trials
2024 · Hope Rugo, Alessandra Gennari, et al. · Cancer Research · 1
133P Intratumoral heterogeneity in localized HR+/HER2– breast cancer at single-cell DNA resolution
2025 · B. Verret, A. Yurchenko, et al. · ESMO Open
PDF
Trajectories of multidimensional worry in survivors of early breast cancer (BC).
2025 · Antonio Di Meglio, Martina Pagliuca, et al. · Journal of Clinical Oncology
PDF
2170 Emulated target trial in the CANTO-RT cohort assessing tumor bed boost in post-menopausal breast cancer patients
2025 · Simon Delaunay, Noémie Simon-Tillaux, et al. · Radiotherapy and Oncology
263P Association between clinicopathological characteristics and pathological complete response in patients with triple negative breast cancer treated by neoadjuvant chemo-immunotherapy
2024 · C. Helal, L. Djerroudi, et al. · Annals of Oncology
FIGURE 3 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
2024 · Maxim De Schepper, Ha-Linh Nguyen, et al.
FIGURE 1 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
2024 · Maxim De Schepper, Ha-Linh Nguyen, et al.
FIGURE 1 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
2024 · Maxim De Schepper, Ha-Linh Nguyen, et al.
Data from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
2024 · Maxim De Schepper, Ha-Linh Nguyen, et al.
Supplementary Figure 1 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
2024 · Maxim De Schepper, Ha-Linh Nguyen, et al.
PDF
FIGURE 5 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
2024 · Maxim De Schepper, Ha-Linh Nguyen, et al.
FIGURE 2 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
2024 · Maxim De Schepper, Ha-Linh Nguyen, et al.
FIGURE 2 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
2024 · Maxim De Schepper, Ha-Linh Nguyen, et al.
Supplementary Figure 12 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
2024 · Maxim De Schepper, Ha-Linh Nguyen, et al.
PDF
Supplementary Figure 2 from Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer–Treated with Neoadjuvant Systemic Therapy
2024 · Maxim De Schepper, Ha-Linh Nguyen, et al.
Works count: 63
Citation count: 255
H-index: 6
I10-index: 5
Year
Topic
Type